GlassScriptPhysician profile
Ellen M Essig
NPI 1568713378
$2,111.71
in general payments reported to CMS, 2019-2025
13 companies · $372 in 2025
The $372 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $289 · 2022: $611 · 2023: $418 · 2024: $422 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,211.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $609.48 | 2021-2025 | |
| Rigel Pharmaceuticals, INC. | $417.25 | 2021-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Alexion Pharmaceuticals, INC. | $170.08 | 2023-2025 | Ultomiris |
| Amgen INC. | $155.00 | 2022-2023 | Xgeva, Nplate |
| Sobi, INC | $143.79 | 2022-2025 | |
| Dova Pharmaceuticals | $143.26 | 2021 | |
| Genzyme Corporation | $124.36 | 2022-2025 | |
| Daiichi Sankyo INC. | $101.56 | 2022-2024 | Injectafer |
| Shield Therapeutics INC | $73.97 | 2024-2025 | |
| Apellis Pharmaceuticals, INC. | $68.93 | 2025 | Empaveli |
| Pharmacyclics LLC, An Abbvie Company | $50.25 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $30.39 | 2023 | Reblozyl |
| Bayer Healthcare Pharmaceuticals INC. | $23.39 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ellen Essig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.